|Articles|December 15, 2022

FDA Funds Initiative to Address Disparities in Real World Data

The FDA tapped the Reagan-Udall Foundation to launch the initiative.

The Reagan-Udall Foundation for the FDA (FDA Foundation) is launching the Real-world Accelerator to Improve the Standard of collection and curation of race and ethnicity data in health care (RAISE). The initiative, funded by the Food and Drug Administration’s Office of Minority Health and Health Equity (OMHHE), focuses on understanding, aligning, and disseminating best practices to improve real-world reporting, collection, curation, and integration of race and ethnicity data.

Efforts to improve race and ethnicity data collection and curation cross the domains of health disparities and health equity research, health care finance, health IT, workforce training, practice standards, and policy development. RAISE will convene a diverse group of leaders from across the health care ecosystem to collaborate on actionable solutions to improve the collection and curation of race and ethnicity data in health care settings, ultimately improving the quality of health care and medical products.

Continue reading this story here.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.